Search Results

There are 26393 results for: content related to: Fed-batch bioreactor process scale-up from 3-L to 2,500-L scale for monoclonal antibody production from cell culture

  1. You have free access to this content
    CD22 ligation inhibits downstream B cell receptor signaling and Ca2+ flux upon activation

    Arthritis & Rheumatism

    Volume 65, Issue 3, March 2013, Pages: 770–779, N. Sieger, S. J. Fleischer, H. E. Mei, K. Reiter, A. Shock, G. R. Burmester, C. Daridon and T. Dörner

    Version of Record online : 25 FEB 2013, DOI: 10.1002/art.37818

  2. Production and scale-up of a monoclonal antibody against 17-hydroxyprogesterone

    Biotechnology Progress

    Volume 29, Issue 1, January/February 2013, Pages: 154–164, Gek Kee Chua, Badarulhisam Abdul-Rahman and Yusuf Chisti

    Version of Record online : 4 DEC 2012, DOI: 10.1002/btpr.1656

  3. Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2

    Pediatric Blood & Cancer

    Volume 62, Issue 7, July 2015, Pages: 1171–1175, Elizabeth A. Raetz, Mitchell S. Cairo, Michael J. Borowitz, Xiaomin Lu, Meenakshi Devidas, Joel M. Reid, David M. Goldenberg, William A. Wegener, Hui Zeng, James A. Whitlock, Peter C. Adamson, Stephen P. Hunger and William L. Carroll

    Version of Record online : 2 MAR 2015, DOI: 10.1002/pbc.25454

  4. You have free access to this content
    Durable complete responses from therapy with combined epratuzumab and rituximab


    Volume 113, Issue 10, 15 November 2008, Pages: 2714–2723, John P. Leonard, Stephen J. Schuster, Christos Emmanouilides, Felix Couture, Nick Teoh, William A. Wegener, Morton Coleman and David M. Goldenberg

    Version of Record online : 13 OCT 2008, DOI: 10.1002/cncr.23890

  5. You have free access to this content
    Treatment of systemic lupus erythematosus with epratuzumab

    British Journal of Clinical Pharmacology

    Volume 71, Issue 2, February 2011, Pages: 175–182, Pawel Traczewski and Lidia Rudnicka

    Version of Record online : 28 JUL 2010, DOI: 10.1111/j.1365-2125.2010.03767.x

  6. You have full text access to this OnlineOpen article
    Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

    Arthritis & Rheumatology

    Volume 69, Issue 2, February 2017, Pages: 362–375, Megan E. B. Clowse, Daniel J. Wallace, Richard A. Furie, Michelle A. Petri, Marilyn C. Pike, Piotr Leszczyński, C. Michael Neuwelt, Kathryn Hobbs, Mauro Keiserman, Liliana Duca, Kenneth C. Kalunian, Catrinel Galateanu, Sabine Bongardt, Christian Stach, Carolyn Beaudot, Brian Kilgallen, Caroline Gordon and on behalf of the EMBODY Investigator Group

    Version of Record online : 28 JAN 2017, DOI: 10.1002/art.39856

  7. You have free access to this content
    Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study

    Arthritis Care & Research

    Volume 68, Issue 4, April 2016, Pages: 534–543, D. J. Wallace, K. Hobbs, M. E. B. Clowse, M. Petri, V. Strand, M. Pike, J. T. Merrill, P. Leszczyński, C. M. Neuwelt, S. Jeka, F. Houssiau, M. Keiserman, J. Ordi-Ros, S. Bongardt, B. Kilgallen, C. Galateanu, K. Kalunian, R. Furie and C. Gordon

    Version of Record online : 24 MAR 2016, DOI: 10.1002/acr.22694

  8. Active dimer of Epratuzumab provides insight into the complex nature of an antibody aggregate

    Journal of Pharmaceutical Sciences

    Volume 95, Issue 1, January 2006, Pages: 126–145, Richard L. Remmele Jr., William J. Callahan, Sampathkumar Krishnan, Linda Zhou, Pavel V. Bondarenko, Andrew C. Nichols, Gerd R. Kleemann, Gary D. Pipes, Sungae Park, Szilan Fodor, Eva Kras and David N. Brems

    Version of Record online : 28 NOV 2005, DOI: 10.1002/jps.20515

  9. You have free access to this content
    2015 ACR/ARHP Annual Meeting Abstract Supplement

    Arthritis & Rheumatology

    Volume 67, Issue S10, October 2015, Pages: 1–4046,

    Version of Record online : 5 NOV 2015, DOI: 10.1002/art.39448

  10. You have free access to this content
    SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia

    British Journal of Haematology

    Volume 165, Issue 4, May 2014, Pages: 504–509, Anjali S. Advani, Shannon McDonough, Steven Coutre, Brent Wood, Jerald Radich, Martha Mims, Margaret O'Donnell, Stephanie Elkins, Michael Becker, Megan Othus and Frederick R. Appelbaum

    Version of Record online : 3 MAR 2014, DOI: 10.1111/bjh.12778

  11. Aggressive Non-Hodgkin's Lymphomas

    Standard Article

    Wiley Handbook of Current and Emerging Drug Therapies

    Published Online : 15 SEP 2006, DOI: 10.1002/9780470041000.cedt003

  12. BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+Ph+B-ALL: proof of principle

    European Journal of Haematology

    Volume 91, Issue 6, December 2013, Pages: 552–556, Patrice Chevallier, Caroline Bodet-Milin, Nelly Robillard, Thomas Eugene, Audrey Menard, Claire Le Houerou, Thierry Guillaume, Jacques Delaunay, Martine Escoffre-Barbe, William A. Wegener, David M. Goldenberg and Francoise Kraeber-Bodéré

    Version of Record online : 12 SEP 2013, DOI: 10.1111/ejh.12183

  13. Scale-up analysis for a CHO cell culture process in large-scale bioreactors

    Biotechnology and Bioengineering

    Volume 103, Issue 4, 1 July 2009, Pages: 733–746, Zizhuo Xing, Brian M. Kenty, Zheng Jian Li and Steven S. Lee

    Version of Record online : 9 FEB 2009, DOI: 10.1002/bit.22287

  14. You have free access to this content
    A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma


    Volume 107, Issue 12, 15 December 2006, Pages: 2826–2832, Ivana N. M. Micallef, Brad S. Kahl, Matthew J. Maurer, Ahmet Dogan, Stephen M. Ansell, Joseph P. Colgan, Susan Geyer, David J. Inwards, William L. White and Thomas M. Habermann

    Version of Record online : 10 NOV 2006, DOI: 10.1002/cncr.22342

  15. You have free access to this content
    Current status of antibody therapy in ALL

    British Journal of Haematology

    Volume 168, Issue 4, February 2015, Pages: 471–480, Jing Ai and Anjali Advani

    Version of Record online : 10 NOV 2014, DOI: 10.1111/bjh.13205

  16. You have free access to this content
    Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies

    Clinical & Experimental Immunology

    Volume 167, Issue 1, January 2012, Pages: 7–14, A. Vossenkämper, P. M. K. Lutalo and J. Spencer

    Version of Record online : 1 DEC 2011, DOI: 10.1111/j.1365-2249.2011.04460.x

  17. You have free access to this content
    Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides


    Volume 116, Issue S4, 15 February 2010, Pages: 1134–1145, Robert M. Sharkey, Habibe Karacay and David M. Goldenberg

    Version of Record online : 2 FEB 2010, DOI: 10.1002/cncr.24802

  18. You have free access to this content
    B cell therapy with the anti-CD22 monoclonal antibody epratuzumab: Comment on the editorial by St.Clair and Tedder

    Arthritis & Rheumatism

    Volume 54, Issue 7, July 2006, Page: 2344, David M. Goldenberg, Rhona Stein, John P. Leonard, Serge D. Steinfeld, Thomas Dörner and Gerd R. Burmester

    Version of Record online : 26 JUN 2006, DOI: 10.1002/art.21937

  19. Bioreactor environment-sensitive sentinel genes as novel metrics for cell culture scale-down comparability

    Biotechnology Progress

    Volume 28, Issue 5, September/October 2012, Pages: 1138–1151, Bhargavi Kondragunta, Bharat H. Joshi, Jing Han, Kurt A. Brorson, Raj K. Puri, Antonio R. Moreira and Govind Rao

    Version of Record online : 18 SEP 2012, DOI: 10.1002/btpr.1606

  20. Epratuzumab modulates B-cell signaling without affecting B-cell numbers or B-cell functions in a mouse model with humanized CD22

    European Journal of Immunology

    Volume 46, Issue 9, September 2016, Pages: 2260–2272, Lamia Özgör, Carolin Brandl, Anthony Shock and Lars Nitschke

    Version of Record online : 25 JUL 2016, DOI: 10.1002/eji.201646383